FIELD: biochemistry.
SUBSTANCE: present invention relates to a novel peptide compound capable of blocking pain signal transmission. Invention object is an analogue of conotoxin RgIA, in which disulphide bonds are modified to thioester bonds. Novel analogue shows high biological and physiological activity.
EFFECT: invention can be used in preparing drug preparations for treating pain of various aetiology.
2 cl, 8 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE HAVING HIGH AFFINITY TO TYPE ALPHA7 HUMAN NICOTINIC RECEPTOR AND USE THEREOF | 2011 |
|
RU2455359C1 |
| PEPTIDE AZEMYOPSYN SELECTIVELY REACTING WITH NICOTINE MUSCARINIC RECEPTORS AND APPLICABLE AS MYORELAXANT IN MEDICINE AND COSMETOLOGY | 2011 |
|
RU2473559C1 |
| PEPTIDE PURINOCEPTOR MODULATOR | 2010 |
|
RU2422459C1 |
| PEPTIDES AND THEIR DERIVATIVES WHICH INTERACT WITH NICOTINIC ACETYLCHOLINE RECEPTOR AND SUITABLE FOR USE IN COSMETOLOGY AGAINST MIMIC AND AGE-RELATED WRINKLES | 2013 |
|
RU2524428C1 |
| ALPHA-CONOTOXIN PnIA ANALOGUE SHOWING HIGH AFFINITY AND SELECTIVITY TO ACETYLCHOLINE-BINDING PROTEIN FROM APLYSIA CALIFORNICA | 2011 |
|
RU2458068C1 |
| ACTINIA POLYPEPTIDE HAVING ANALGETIC ACTION | 2008 |
|
RU2368621C1 |
| PEPTIDE MODULATOR OF PURINERGIC RECEPTORS | 2016 |
|
RU2650780C1 |
| METHOD OF STIMULATING CHRONIC PAIN OF MALIGNANT GROWTH IN LUNG RATS | 2018 |
|
RU2676641C1 |
| PEPTIDE HAVING LYNX1 PROTEIN ACTIVITY (EMBODIMENTS), PHARMACEUTICAL COMPOSITION FOR TREATING ANXIETY DISORDERS AND DEPRESSION OR CORRECTION OF COGNITIVE DISORDERS IN NEURODEGENERATIVE DISEASES, CONTAINING SAID PEPTIDE, AND METHOD OF TREATING AND CORRECTING SAID DISORDERS | 2020 |
|
RU2734649C1 |
| NONCYTOTOXIC SUBSTANCE, METHOD OF REGULATION OF NEUROMEDIATOR OR NEUROMODULATOR RELEASE FROM PRIMARY SENSORY AFFERENT CELLS AND METHOD FOR REGULATION OF NEUROMEDIATOR OR NEOROMODULATOR RELEASE FROM PRIMARY NOCICEPTIVE AFFERENT CELLS | 1996 |
|
RU2165976C2 |
